Cargando…
The Economic Costs of Progressive Supranuclear Palsy and Multiple System Atrophy in France, Germany and the United Kingdom
Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are progressive disabling neurological conditions usually fatal within 10 years of onset. Little is known about the economic costs of these conditions. This paper reports service use and costs from France, Germany and the UK and...
Autores principales: | McCrone, Paul, Payan, Christine Anne Mary, Knapp, Martin, Ludolph, Albert, Agid, Yves, Leigh, P. Nigel, Bensimon, Gilbert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169589/ https://www.ncbi.nlm.nih.gov/pubmed/21931694 http://dx.doi.org/10.1371/journal.pone.0024369 |
Ejemplares similares
-
Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALE
por: Payan, Christine A. M., et al.
Publicado: (2011) -
A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability
por: Rolland, Yan, et al.
Publicado: (2011) -
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
por: Bensimon, Gilbert, et al.
Publicado: (2009) -
Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy
por: Brown, Jesse A., et al.
Publicado: (2017) -
Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases
por: Chen, Jason A., et al.
Publicado: (2018)